Advertisement
Advertisement
ALXO
ALX Oncology Holdings Inc. Common Stock
1.94
USDSponsored
-0.01
-0.51%
Jul 31, 15:59 UTC -4
Closed
Pre-Market
1.95
+0.01
+0.26%
ALXO Earnings Reports
Positive Surprise Ratio
ALXO beat 13 of 24 last estimates.
54%
Next Report
In 3 Days
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.14
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-67.44%
ALX Oncology Holdings Inc. Common Stock earnings per share and revenue
On May 08, 2026, ALXO reported earnings of -0.14 USD per share (EPS) for Q1 26, beating the estimate of -0.19 USD, resulting in a 26.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +11.23% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.00
Surprise
-90.05%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.13%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.46
Actual
$14.29
Surprise
+36.51%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.21
Surprise
-23.70%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
FAQ
What were ALX Oncology Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ALX Oncology Holdings Inc. Common Stock reported EPS of -$0.14, beating estimates by 26.23%, and revenue of $0.00, 0% as expectations.
How did the market react to ALX Oncology Holdings Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 11.23%, changed from $1.87 before the earnings release to $2.08 the day after.
When is ALX Oncology Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for ALX Oncology Holdings Inc. Common Stock's next earnings report?
Based on 6
analysts, ALX Oncology Holdings Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement